Is it necessary to take long-term use of Asnib/Asiminib (Sinbel) and its medication strategy?

Asciminib (Asciminib) is an inhibitor targeting BCR-ABL1 and is mainly used for patients with chronic myelogenous leukemia (CML), especially those who are resistant or intolerant to imatinib, dasatinib or nilotinib. Since CML is a chronic progressive disease, targeted therapy usually requires continuous control of BCR-ABL1 activity to prevent disease recurrence or accelerate stage progression. Therefore, asinib is designed for long-term, continuous administration in most clinical regimens to maintain molecular response and disease stabilization.

The routine clinical dose is usually 40mg 2 times a day . The specific dose needs to be adjusted individually based on the patient's mutation type, tolerance and previous medication history. In order to reduce the risk of drug resistance, low doses are usually started at the initial stage of treatment and gradually adjusted under the guidance of a doctor. During long-term use, it is necessary to regularly monitor blood cells, liver and kidney functions, and molecular levels of BCR-ABL1 to evaluate efficacy and safety and ensure that the drug dose can maintain efficacy while minimizing side effects.

Long-term use of asinib may cause mild adverse reactions, such as decreased platelets, abnormal liver function or gastrointestinal discomfort. Patients should cooperate with regular laboratory examinations, and promptly adjust the dose or take symptomatic treatment when obvious abnormalities occur. Doctors usually decide whether dose maintenance or adjustment is needed based on molecular monitoring results to ensure that the treatment is safe and effective. Following a strict follow-up plan is crucial for long-term control of CML and delaying disease progression.

Although asinib usually needs to be taken long-term, the treatment plan should be individually adjusted based on the patient's efficacy, tolerance and concomitant medications. Some patients with stable disease and complete molecular response may consider extending the medication interval or gradually reducing the dose under the evaluation of a professional doctor, but this must be done under strict monitoring. Overall, Asnib's long-term medication strategy emphasizes continuous disease suppression, regular monitoring and individualized adjustments to achieve optimal efficacy and lowest risks, providing a robust long-term treatment option for CML patients.

Reference materials:https://www.drugs.com/